supernatant cell concentration was found between 4 5 u00d7 10 6 cells ml cell viability during the exponential growth phase was about 85 specific growth rate varied between 0 015 0 025 h u2212 1 igg concentration was found between 70 120 mg l in another embodiment of the present invention long term stability of stable high producer cell clones was evaluated by performing kinetic studies after 30 60 and 90 days in continuous cell culture specific growth rate p and specific production rate qp were determined in still another embodiment of the present invention identity attributes of the secreted immunoglobulin by selected stable high producer cell clones were determined disclosure of such identity attributes operationally defines the molecular phenotype of this therapeutic antibody 14f7h in still another embodiment of the present invention in vitro and in vivo anti tumor activity of the recombinant antibody 14f7h were evaluated fig1 cell adaptation to pfhm ii medium at different concentrations of cell boost 5 fig2 fermentation run in 5 l bioreactor using the cells adapted to pfhm ii medium without cell boost 5 fig3 absorbance values from the recognition elisa black line is the median of the results purified 1 u03bcg ml of t1h and hr3 were used as negative controls selected clones 35d8 35d6 31e7.